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HIV persistence
Since the early days of highly active antiretroviral therapy 
(HAART), it has been clear that, despite strong and long-lasting 
suppression of the virus in peripheral blood, HIV can persist in 
patients indefinitely. Moreover, interruption of treatment leads to 
a rapid rebound of plasma viremia to levels similar to those exist-
ing prior to therapy initiation (1–6). This recrudescence is believed 
to be the result of the reactivation of latently infected cells present 
in the peripheral blood and tissues of ART-suppressed patients. 
Latently infected T cells in the peripheral blood represent the 
most extensively studied and best-characterized HIV reservoir 
in patients. The contribution of other hematopoietic cells to HIV 
persistence is currently the subject of intense investigation and 
debate (7–9). However, little information is currently available 
regarding latently infected cells in tissues.
In the literature, the term “HIV reservoir” has been used to 
indicate a number of different measures of HIV, such as viral DNA 
(vDNA), vRNA, viral proteins, and virus outgrowth from T cells 
stimulated ex vivo. The overall HIV reservoir contributing to per-
sistence in ART-treated individuals might include some low level 
of actively replicating virus or chronically infected cells. For the 
purposes of this Review, we will define the latent HIV reservoir 
(i.e., not expressing functional proviruses) as the absolute num-
ber of long-lived, resting, latently infected cells that, upon stimu-
lation in vivo or ex vivo, can produce replication-competent virus 
capable of reestablishing the infection. We use this strict definition 
because it most closely describes the target that must ultimately be 
destroyed to truly rid the body of infection. Therefore, the HIV res-
ervoir is composed of all the latently infected, long-lived, resting, 
inducible cells present in all tissues and the peripheral blood of an 
infected individual.
The gold standard for measurement of the HIV reservoir in 
patients is the quantitative viral outgrowth assay (QVOA) per-
formed on resting peripheral blood cells obtained from fully sup-
pressed patients that are induced ex vivo using maximal stimu-
lation to produce virus (10–14). This peripheral blood reservoir 
of latently infected cells has been shown to persist for decades 
and to have an extremely long half-life (13, 15). However, it is 
likely that in humans, long-lived, resting, latently infected cells 
also exist in tissues (1). Some tissues including the brain have 
been referred to as sanctuaries for viral persistence, because 
infected cells located within these tissues may be extremely 
difficult to eliminate due to a lack of drug penetrance (16, 17). 
Currently, there are ethical and practical issues that prevent the 
study of the HIV reservoir in human tissues. Similar ethical and 
practical considerations prevent the evaluation of novel clinical 
approaches to HIV eradication, because their implementation 
might pose unnecessary risk to an otherwise relatively healthy 
group of individuals undergoing safe and effective treatment 
for HIV infection (18, 19). Therefore, detailed investigation of 
the molecular basis of HIV persistence in vivo, as well as in vivo 
evaluation of novel approaches to HIV eradication, require the 
use of animal models that faithfully (or at least adequately) 
reflect key aspects of the human condition. The two types of 
models currently available for this type of research are nonhu-
man primates (NHPs) and humanized mice. This Review will 
examine the utility of these models to investigate HIV latency, 
persistence, reactivation, and eradication, with an emphasis on 
recent work done in humanized mice.
HIV species specificity and tropism
HIV is a pathogen of humans and is not known to cause disease 
in any other species. Although HIV is human tropic, it can also 
replicate in chimpanzees (20–24). HIV cannot infect or repli-
cate in other species of commonly used laboratory animals like 
mice, rats, rabbits, and macaques (25–29). The species speci-
ficity of HIV for humans is multifactorial and not limited to the 
interactions of viral surface proteins with human cell-surface 
receptors. For example, coexpression of the cell-surface HIV 
receptor (human CD4) and either of its coreceptors (CCR5 or 
HIV persistence in patients undergoing antiretroviral therapy is a major impediment to the cure of HIV/AIDS. The molecular 
and cellular mechanisms underlying HIV persistence in vivo have not been fully elucidated. This lack of basic knowledge has 
hindered progress in this area. The in vivo analysis of HIV persistence and the implementation of curative strategies would 
benefit from animal models that accurately recapitulate key aspects of the human condition. This Review summarizes the 
contribution that humanized mouse models of HIV infection have made to the field of HIV cure research. Even though these 
models have been shown to be highly informative in many specific areas, their great potential to serve as excellent platforms 
for discovery in HIV pathogenesis and treatment has yet to be fully developed.
In vivo platforms for analysis of HIV persistence  
and eradication
J. Victor Garcia
Division of Infectious Diseases, UNC Center for AIDS Research, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
Conflict of interest: The author has declared that no conflict of interest exists.
Reference information: J Clin Invest. 2016;126(2):424–431. doi:10.1172/JCI80562.
The Journal of Clinical Investigation   R e v i e w  S e R i e S :  H i v
4 2 5jci.org   Volume 126   Number 2   February 2016
Reconstitution of immunodeficient mice with 
CD34+ cells
As discussed above, John Dick and colleagues demonstrated that 
immunodeficient mice could be partially reconstituted with human 
cells after bone marrow transplantation with human CD34+ cells 
(37, 38, 42). Early on, relatively low levels of reconstitution were 
noted when using several different strains of immunodeficient 
mice. Subsequently, significantly better levels of human reconstitu-
tion were observed when NOD/SCID mice were transplanted with 
human CD34+ cells (39, 41, 42). Surprisingly and almost invariably, 
only human B and myeloid cells were present in the reconstituted 
mice. For the most part, all of the mice reconstituted with CD34+ 
cells were devoid of human T cells. Obviously, this represented a 
significant limitation for the use of these models in HIV research. 
The lack of T cells in NOD/SCID mice was overcome by implan-
tation of human thymic tissue, as indicated below for BLT mice 
(53). In addition, three newly introduced immunodeficient mouse 
strains, Rag1–/– common gamma chain–/– (DKO), NOD Rag1–/– com-
mon gamma chain –/– (NRG), and NSG mice, were able to produce 
human T cells using the endogenous mouse thymus (47–49). Since 
then, numerous additional strains of immunodeficient mice have 
been shown to support endogenous human T cell production after 
bone marrow transplantation with human CD34+ cells (54–57). 
Some of these models have been used to study HIV persistence.
Strengths and limitations of current humanized 
mouse models
The humanized mouse models currently available for biomedi-
cal research differ in their level of complexity. In all cases, they 
are capable of replicating both HIV-1 and -2. Viral replication 
takes place in human cells present in both the peripheral blood 
and tissues. The human cells present in these animals have been 
shown to induce both innate and adaptive immune responses 
(46, 53, 58–61). In addition, HIV infection in these models 
responds to the same drugs used in humans (62–68). Like all 
animal models for biomedical research, there are limitations to 
their use in HIV research. Some of these limitations are intrinsic 
and are related to the size and biology of the animal, including 
the relatively small volume of blood plasma that can be obtained 
for viral load analysis, the limited amount of peripheral blood 
cells that can be used for in vitro functional analysis, and the 
relatively short lifespan of the animal. In this regard, human-
ized mice can be considered a useful accelerated model for the 
rapid evaluation of relevant interventions. Other limitations 
are related to the nature of the xenografts between humans and 
mice. For example, the structure of secondary lymphoid tissues 
found in humanized mice does not fully replicate the structures 
observed in human tissues. Moreover, some highly engrafted 
animals develop a wasting disease (47, 69). However, these 
problems have been addressed in humanized mice generated 
in new immunodeficient mouse strains (55). Even though most 
humanized mouse models are capable of mounting adaptive 
immune responses, these are not optimal, and efforts are under-
way to improve them (46, 47, 70, 71). Nevertheless, the current 
humanized mouse models have been used extensively to test 
the efficacy of numerous immune approaches to control HIV 
replication and kill infected cells in vivo (67, 72–74).
CXCR4) does not render mouse or rat cells competent to sup-
port virus replication (26, 29). Viral restriction factors, includ-
ing tripartite motif–containing protein 5α (TRIM5α) and apo-
lipoprotein B mRNA–editing enzyme, catalytic polypeptide 3 
(APOBEC3), also severely limit the ability of HIV to replicate in 
other species (30–36). These barriers to HIV replication in mul-
tiple species have resulted in a lack of adequate animal models 
to study basic aspects of HIV replication, pathogenesis, latency, 
and persistence.
An introduction to humanized mouse models
In the early 1980s, pioneering work from the laboratory of John 
E. Dick and others established the repopulation of immuno-
deficient mice with human hematopoietic stem cells (HSCs) 
(37–42). Since then, many different types of “humanized mice” 
have been described, and these models have been reviewed 
extensively elsewhere (43–46). Virtually all modern human-
ized mouse models (Figure 1) are produced via transplantation 
of human CD34+ HSCs and/or human tissues into one of sev-
eral different strains of immunodeficient mice (46), resulting 
in systemic or local reconstitution with human hematopoietic 
cells that, depending on the model, can include human B cells, 
monocytes and macrophages, DCs, and T cells. When human-
ized mice are generated via the transplantation of human CD34+ 
stem cells, human T cells are produced in only certain strains. In 
these specific mouse strains, the human T cells generated from 
transplanted CD34+ cells are produced in the mouse thymus 
and are presumed to be educated in the context of mouse MHC 
class I and II (47–49). However, in humanized mouse models 
in which human liver and thymus tissues are implanted under 
the kidney capsule to create a functional human thymus (SCID- 
hu thy/liv mice, T cell–only mice [ToM], and bone marrow/
liver/thymus [BLT] mice), T cells can develop in the presence of 
human thymic epithelium, resulting in HLA I and II restriction 
(50, 51). BLT mice differ from SCID-hu thy/liv mice and ToM, in 
that they receive an autologous human bone marrow transplant 
after the implantation of human liver and thymus tissues from 
which T cell progenitors and other human hematopoietic cells 
are derived, resulting in systemic reconstitution with virtually 
all other types of human hematopoietic cells (52, 53). Addition-
ally, several new strains of mice have recently been used to gen-
erate humanized mice, some of which have been used to study 
relevant aspects of HIV persistence in vivo. Table 1 describes the 
different mouse strains used for the work discussed herein.
Table 1. Mouse strains commonly used to make humanized mice 
to study HIV latency, persistence, and eradication strategies
Strain Abbreviation Models for which it has been used
PrkdcSCID SCID thy/liv implant
NOD.CB17-PrkdcSCID/J NOD/SCID BLT
NOD.Cg-PrkdcSCID Il2rgtm1Wjl/SzJ NSG BLT, CD34 transplant and ToM
NOD.Rag1–/– IL2rγ–/– NRG CD34 cell transplant
BALB/c-Rag1−/− γc−/− DKO CD34 cell transplant
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Analysis of HIV latency and persistence in ToM
Despite its utility in the investigation of HIV infection and per-
sistence in thymocytes, the SCID-hu thy/liv model is some-
what limited, given that SCID-hu thy/liv mice possess very few 
systemic human T cells and infection of the thymic organoid 
results in low levels of plasma viremia. The advent of a new and 
improved immunodeficient mouse strain has made it possible 
to expand the usefulness of this type of tissue implant model 
by providing increased levels of peripheral and systemic recon-
stitution with human T cells. Implantation of thy/liv tissue into 
NSG mice results in the development of a thymic organoid 
similar to the one that develops in SCID-hu thy/liv mice (83). 
However, in striking contrast with the virtual absence of human 
T cells in the periphery and tissues of SCID-hu thy/liv mice, NSG 
thy/liv mice have significant levels of human T cells in all tissues 
analyzed, including peripheral blood, spleen, thymus, lymph 
nodes, bone marrow, liver, and lung (83). What sets this model 
apart from the NSG mice transplanted with human CD34+ cells 
(described below) is the complete absence of human antigen- 
presenting cells (APCs). Specifically, NSG thy/liv mice are 
devoid of any human B cells, monocytes, macrophages, or DCs. 
Thus, these animals have been functionally designated as ToM 
(83). Unlike other humanized mouse models with high lev-
els of systemic reconstitution with human T cells, ToM do not 
develop signs of graft-versus-host disease (GVHD) (83). ToM 
are susceptible to HIV infection and support high levels of viral 
replication, as determined by the analysis of plasma vRNA, and 
viremia is maintained for the lifespan of the animals. Consistent 
with the systemic distribution of human CD4+ T cells, HIV-in-
fected cells can be found in all tissues examined. ART efficiently 
suppresses viremia in these mice, and structured treatment 
interruption results in viral rebound (83). In order to determine 
whether HIV latency is established in this model, cells obtained 
from suppressed animals were harvested from multiple tissues, 
Analysis of HIV persistence in SCID-hu thy/liv 
humanized mice
SCID-hu thy/liv mice were originally described by McCunne et 
al. as a murine model for the analysis of human hematolymphoid 
differentiation and function (75). Shortly thereafter, Namikawa 
et al. demonstrated that these mice were susceptible to HIV 
infection when virus was directly injected into the human thy-
mic organoid that develops in these animals (76). The utility of 
this model to investigate the genesis of HIV latency was demon-
strated by Brooks et al. (77), who used SCID-hu thy/liv mice to 
show that HIV latency could be generated during thymopoiesis 
and that this process could contribute to the systemic establish-
ment of HIV latency in peripheral organs. The authors postulated 
that CD4 and CD8 double-positive thymocytes were targets of 
HIV infection and that the transcriptional silencing that occurs 
during thymopoiesis silenced the HIV promoter, resulting in 
latently infected, single-positive CD4 T cells capable of exiting 
the thymus into the periphery and seeding the spleen. Consis-
tent with their hypothesis, the authors were also able to detect 
HIV in CD8 single-positive cells. Ex vivo induction of both cell 
types with either anti-human CD3 Abs or cytokines resulted in 
the production of virus. The authors concluded that HIV latency 
was readily established in thymocytes and that this process was 
a significant contributor to thymic and systemic HIV persistence. 
In subsequent work, the authors also investigated the role of 
NF-κB in HIV reactivation and used in vivo–generated, latently 
infected cells for ex vivo activation studies aimed at investigating 
T cell–signaling pathways that stimulated latent HIV in primary 
cells (78). Further analysis demonstrated that latent HIV could 
be reactivated ex vivo using prostratin and IL-7 (79, 80). The 
SCID-hu thy/liv model was also used to demonstrate the efficacy 
of immunotoxins in killing latently infected cells after reactiva-
tion ex vivo (81) and in killing infected thymocytes in animals 
undergoing combination ART (82).
Figure 1. Different humanized mouse models 
used for in vivo analysis of HIV latency and 
persistence. The different strains of animals 
commonly used to generate humanized mice 
after CD34+ cell transplantation and/or tissue 
implantation are indicated. In all cases, mice 
are preconditioned with radiation prior to trans-
plantation with CD34+ cells and tissue implan-
tation. Note that in some instances, such as in 
the case of BLT mice and ToM, the same strain 
of mouse is reconstituted with different sets of 
human hematopoietic cells.
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presumed to be transcriptionally silent, they are also presumed 
to not express HIV antigens and are therefore not expected to be 
recognized by the immune system, therapeutic Abs, or ex vivo–
generated chimeric antigen receptor (CAR) T cells. In order to 
engage any of these approaches in the destruction of infected 
cells, latently infected cells must first be induced to express HIV, 
a process known as latency reversal. Three latency-reversing 
agents (LRAs), vorinostat, I-BET151, and cytotoxic T lympho-
cyte antigen 4 (CTLA-4), were evaluated in humanized NRG 
mice for their ability to prevent or delay viral rebound (72). LRAs 
were administered individually or in combination to infected 
NRG humanized mice that were previously suppressed for 20 
days with a combination of three mAbs (3BNC117, 10-1074, and 
PG16) (72). LRAs were administered for 5 to 14 days, and the 
mice were monitored for viral rebound for an additional 45 to 
85 days. Individual inducers had no discernible effect on viral 
rebound: of the suppressed infected animals receiving a single 
inducer, 31 of 33 mice rebounded. In contrast, of the animals 
receiving the combination of three different inducers that were 
under evaluation for an additional 62 to 105 days, 57% failed to 
show viral rebound, suggesting a possible reduction in the viral 
reservoir (72).
Analysis of HIV latency in DKO mice 
reconstituted with human CD34+ cells
DKO humanized mice efficiently replicate HIV after an i.v. or 
vaginal exposure (66, 95–98). Using a detailed pharmacokinetic 
analysis of plasma drug levels, Chaudhary et al. implemented 
a drug regimen consisting of tenofovir, emtricitabine, and the 
strand-transfer inhibitor L-870812, which was capable of effi-
ciently suppressing HIV replication in most HIV-infected DKO 
humanized mice, as determined by plasma viral load analysis 
(99). In animals in which viral suppression was not complete, the 
authors were able to demonstrate the development of drug-re-
sistant viruses. Discontinuation of therapy after viral suppres-
sion resulted in rapid viral rebound and loss of peripheral CD4+ 
T cells, demonstrating that this model recapitulated key aspects 
of human HIV infection. In a subsequent communication that 
used the same methodology, Choudhary et al. investigated the 
establishment of HIV latency in infected DKO humanized mice 
(100). In these studies, the investigators isolated resting CD4+ 
T cells from the tissues of untreated and ART-suppressed 
HIV-infected mice. The cells were incubated ex vivo with 
human IL-2 (hIL-2), or a combination of hIL-2 and phytohe-
magglutinin (PHA) to induce virus production. The virus was 
allowed to spread to allogeneic, CD8-depleted human periph-
eral blood mononuclear cells (PBMCs), as is routinely done to 
quantitate the levels of latently infected cells in HIV-infected 
patients undergoing suppressive ART (85, 86). These analyses 
indicated that, in this humanized mouse model, HIV latency 
was established and that the number of latently infected cells 
varied between 2 and 12 infectious units per million (IUPM) of 
resting CD4+ T cells, with a median of 8 IUPM. The authors also 
noted that, in some instances, no replication-competent virus 
could be induced in the ex vivo cultures. The failure to detect 
latent virus in these cultures was attributed to the small num-
bers of cells obtained from many of these animals.
and resting CD4+ T cells were isolated for ex vivo induction 
assays. Using the same methodology previously described for 
the quantitation of HIV latency in humans (84–86), ToM were 
shown to establish HIV latency with a frequency similar to that 
observed in chronically infected patients receiving ART (83).
In vivo evaluation of broadly neutralizing Abs for 
HIV treatment
Unlike most conventional drugs used for the treatment of HIV/
AIDS, Abs have numerous functions that, in addition to neutral-
izing infectious virus, can engage multiple aspects of the immune 
system to control infection and possibly kill infected cells in vivo 
(87–89). Some recently discovered Abs have extremely broad 
in vitro neutralization activity. When evaluated individually 
for their ability to control infection in vivo in humanized mice, 
these Abs were shown to provide a short (6–7 days) and variable 
(0.2–1.1 log10) reduction in peripheral blood plasma viral load lev-
els (73). Viral replication in the presence of sustained Ab levels 
was associated with mutations that were mapped to the respective 
Ab-binding site (73). Similar results were obtained when infected 
mice were treated with a combination of three Abs, except that 
there was partial control of infection in 3 of the 12 treated ani-
mals. When a combination of five mAbs was administered to 
infected mice, a dramatic drop in viral load to below the level of 
detection (800 copies of vRNA per milliliter of plasma) was noted 
in 14 of 14 treated animals. This viral suppression was maintained 
for up to 60 days. Despite strong control of viremia in these mice 
by the Ab combination, viral rebound occurred an average of 60 
days after therapy interruption. These results demonstrate the 
utility of humanized mice for the in vivo evaluation of broadly 
neutralizing Abs to suppress viremia. A second combination of 
three Abs in this model exhibited an even greater reduction in 
viral load, which was maintained for the entire course of treat-
ment and accompanied by a reduction (0.8 log10) in vDNA levels 
in peripheral blood (67). Continuous administration of this Ab 
combination to animals previously treated with ART prevented 
viral rebound in some animals after ART cessation. As serum Ab 
levels decreased, the authors observed viral rebound in all ani-
mals. Given these highly encouraging results, single-Ab adminis-
tration during and after ART was evaluated. In this case, selected 
Abs were able to control viremia in some, but not all, mice (67).
As demonstrated by the studies described above, intermit-
tent dosing of Abs is associated with systemic Ab levels that vary 
between animals. Alternative approaches for the delivery of Abs 
have been evaluated in humanized animal models for HIV pre-
vention (90–92). The most common way to deliver sustained 
levels of Abs has been the use of adeno-associated virus (AAV) 
vectors. With regard to the use of sustained delivery of Abs for 
HIV cure approaches, it is important to mention that adminis-
tration of single Abs via AAV transduction in vivo was shown 
to result in better suppression in reconstituted NRG mice than 
intermittent dosing (67).
Evaluation of strategies to induce the latent HIV 
reservoir
Latent reservoirs of HIV are long lived and not directly affected 
by current ARTs (15, 93, 94). Given that latently infected cells are 
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immunotoxin (a toxin conjugated with an Ab targeting the HIV Env 
protein) to ART-suppressed animals resulted in additional dramatic 
decreases in vRNA levels in tissues (74). Analysis of the numbers of 
RNA-producing cells in tissues demonstrated efficient in vivo kill-
ing of infected cells by immunotoxin treatment (74). Because this 
approach only targets the “active” viral reservoir (i.e., cells produc-
ing the Env antigen) and not latently infected cells, the effect of the 
immunotoxin on the latent reservoir was not analyzed. In summary, 
the BLT humanized mouse model has been shown to serve as an 
excellent platform for the evaluation of novel approaches to the elim-
ination of HIV-infected cells in vivo.
Summary and future directions
The utility of humanized mice for the in vivo analysis of HIV 
persistence has been partially demonstrated. Humanized mice 
provide excellent models for the analysis of virtually all aspects 
of HIV persistence and eradication. These include (a) the eval-
uation of different types of highly relevant viruses for infection; 
(b) the analysis of latency and persistence by virtually all human 
cell types that are targets of HIV infection in both the periphery 
and tissues; (c) the evaluation of new and established antiretrovi-
ral drug interventions; and (d) the evaluation of novel induction 
and killing approaches (Figure 2). In addition, because human-
ized mice represent a complex system featuring virtually all cell 
types that are important for adaptive immune responses, they can 
be useful for the in vivo evaluation of novel approaches to curing 
HIV that are based on biological molecules as well as gene and cell 
therapies (105–108). Even though most of the humanized mouse 
models available to date are limited in their ability to mount 
effective Ab responses (70, 109), as indicated above, these mice 
have been shown to be very useful for evaluating the efficacy of 
HIV-specific Ab therapy and other immunotherapeutic interven-
tions such as checkpoint inhibitors, cytokines, and so forth. (105, 
110). The primary limitations of humanized mice in the study of 
HIV latency, persistence, and eradication are the short lifespan of 
these animals and the relatively low volumes of blood and other 
samples that can be obtained. In addition, it should always be kept 
in mind that the human HIV–infected cells are being studied in 
the context of a chimeric mouse/human xenograft; therefore, not 
all of the cellular interactions that occur in humans are fully reca-
pitulated in these models. Furthermore, the interactions between 
the murine and human cells (that obviously are not occurring in 
Analysis of HIV latency and persistence in  
BLT mice
BLT humanized mice are bioengineered by sandwiching a piece of 
human liver tissue between two pieces of human thymus tissue and 
implanting it under the kidney capsule of preconditioned immuno-
deficient mice. The mice then undergo bone marrow transplanta-
tion with autologous HSCs derived from the same liver tissue used 
for the implant (53). As described for SCID-hu thy/liv mice and 
for ToM, the thy/liv implant in BLT mice develops into a bona fide 
human thymic organoid into which human T cell progenitors pro-
duced in the bone marrow can migrate and differentiate through 
all stages of thymocyte development on human thymic epithelium 
in the context of HLA I and II (53). Bone marrow engraftment also 
results in the production of virtually all other human hematopoietic 
cell types, including those directly relevant to HIV research such as 
monocytes, macrophages, and DCs. Human cells in BLT mice are 
systemically distributed throughout all organs analyzed, including 
bone marrow, lymph nodes, spleen, thymus, liver, lung, female and 
male reproductive tracts, and the upper and lower digestive tracts 
(53, 61, 101–103). The wide distribution of human HIV target cells 
in mucosal sites renders BLT mice susceptible to rectal, vaginal, and 
oral HIV infection (55, 61-63, 65, 103, 104). Mucosal or parenteral 
exposure of BLT mice to HIV results in systemic infection and the 
production of both human Ab and T cell responses (55, 59–61).
Detailed pharmacokinetic analysis of plasma drug levels in 
BLT mice (64, 74) has resulted in ART drug combinations con-
sisting of tenofovir, emtricitabine, and raltegravir that efficiently 
suppress virus in plasma to below-detection levels. Suppression is 
maintained as long as ART is administered; however, as discussed 
above for ToM, therapy interruption results in rapid viral rebound 
to levels similar to those present prior to therapy initiation (64). 
The ability to efficiently suppress viral replication in BLT mice 
has facilitated the ex vivo analysis of HIV latency and persistence. 
Using the methodology described above for similar experiments in 
HIV-infected DKO humanized mice (100), analysis of suppressed 
BLT mice demonstrates the presence of latently infected cells at a 
frequency of approximately 8 IUPM resting CD4+ T cells (64).
Longitudinal analysis of cell-associated vRNA levels in the tis-
sues of BLT mice during ART treatment demonstrated a rapid initial 
decrease that plateaued approximately 28 days after ART initiation in 
all tissues analyzed (74). No further decrease in cell-associated vRNA 
levels was observed with continued treatment. Administration of an 
Figure 2. Analysis of “kick and kill” strategies in humanized mice. 
Diagram illustrating the different steps in the process of evaluating 
induction and/or HIV-infected cell–killing strategies in humanized 
mice. Humanized mice are first exposed to HIV via parenteral or 
mucosal routes. Once systemic viremia has been established, antiretro-
viral drugs are administered either orally or via i.p. injection. Once HIV 
is suppressed below the limit of detection, mice can be treated with 
induction and/or killing approaches. Several candidates for induction 
and HIV-infected cell killing are shown. bNAbs, broadly neutralizing 
Abs; ImmTox, immunotoxins.
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humans) should be taken into consideration. Nevertheless, new 
and improved strains of mice and a better understanding of the 
interplay that occurs at the interface between the human immune 
system and that of the mouse will result in improvements that 
will continue to benefit the field of HIV cure research. At present, 
humanized mouse models can be considered excellent platforms 
for the in vivo evaluation of HIV eradication strategies.
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